ALK and interstitial lung disease: AE reports of ILD among ALK TKI users accounted for 3.2% (640/20,064) of the total AEs related to ALK TKIs; of these, 45.9% were related to crizotinib, 8.0% to ceritinib, 24.5% to alectinib, 14.7% to brigatinib, and 6.9% to lorlatinib.